Vendor Intelligence Report: Rethel Jinan New Energy Technology

Published 2 Jul 2026. 20-page investigative report on who is behind Rethel Jinan New Energy Technology: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 7 Finnrick lab tests, Rethel Jinan shows 3 pass / 4 fail — an overall pass rate of 43%. The record is narrow but adverse: Finnrick has data on Tirzepatide only, and failures outnumber passes. Retatrutide, Lipo C, LC120 and other displayed catalog items are not cleared by association; they sit in a Finnrick data gap.

The corporate-footprint review adds a second concern. Rethel presents as a long-running China manufacturer with large employee, branch, asset, export and certification claims, yet the searched Chinese registries, OpenCorporates, LinkedIn, customs sources and certificate/COA paths did not corroborate that scale. WHOIS records and a Facebook promotion that predates the domain registration point to a much more recent public operating footprint.

The website is also part of the risk picture, not just a cosmetic flaw. The report documents budget DIYMySite infrastructure, home-textile template residue on a peptide site, product-listing mislabels, visible PHP/template errors, and a direct-contact ordering path through QQ email and phone numbers with no standard checkout, terms, privacy policy, payment disclosure or batch-level COA library found.

The buyer read is directional: Rethel is a weak choice for Tirzepatide on the supplied lab record, while the broader catalog remains unproven rather than proven bad. The full report resolves the artifact trail, caveats the negative searches, and shows where stricter grading leaves the Tirzepatide picture.

Inside the full report:

  • Appendix A lab table, rating trajectory and methodology-divergence charts for the Finnrick-tested Tirzepatide record
  • Dated evidence timeline comparing the advertised operating history with WHOIS and Facebook artifacts
  • Corporate-identity sweep across Chinese registries, OpenCorporates, LinkedIn, Global Sources and customs databases
  • Website-infrastructure captures showing DIYMySite hosting, template residue, product mislabeling and PHP errors
  • Sales-path review covering QQ/phone ordering, missing checkout, payment disclosures, terms and COA controls
  • Negative-record trail and open leads for the Jinan address, phone numbers, Manager Zhang, Brenda Fisher and fulfillment origin

Risk assessment

  • Tirzepatide quality-control risk — high: Tirzepatide is the only Finnrick-tested product; 7 tests show 3 pass / 4 fail and a 66.11% current Finnrick rating.
  • Unverifiable manufacturer identity risk — high: Claims of 2006 founding, 1000+ personnel, 60+ branches and 90 million yuan assets are unsupported by registry searches; domain registered July 14, 2025.
  • Direct-contact payment and buyer-recourse risk — medium: No checkout, payment methods, privacy policy or terms were found; orders route through QQ email and phone contacts.
  • Operational infrastructure and site-integrity risk — medium: DIYMySite hosting, template home-textile residue, product mislabeling, visible PHP errors and a one-year domain lifecycle undercut operational reliability.